Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13869022 | 0.84 | KDR (0.37) | MAPK1HPGDKDRKDM4EMAPT | |
| SCHEMBL12365528 | 0.84 | MAPK1 (0.41) | MAPK1HPGDKDRKDM4EMAPT | |
| SCHEMBL12537629 | 0.84 | KDM4E (0.42) | KDM4EMYCKMT2AALDH1A1 | |
| SCHEMBL14537333 | 0.83 | NTRK1 (0.44) | MAPK1HPGDKDRKDM4EPIK3CD | |
| SCHEMBL13695383 | 0.82 | MAPK1 (0.38) | MAPK1HPGDKDRKDM4EMAPT | |
| SCHEMBL13695385 | 0.80 | MBOAT4 (0.37) | MAPK1HPGDKDRKDM4EMAPT | |
| SCHEMBL13695386 | 0.80 | EGLN2 (0.42) | MAPK1HPGDKDRKDM4EMAPT | |
| SCHEMBL12365652 | 0.77 | MAPK1 (0.37) | MAPK1HPGDKDRKDM4EMAPT | |
| SCHEMBL12365533 | 0.76 | MAPK1 (0.36) | MAPK1HPGDKDRKDM4EMAPT | |
| SCHEMBL13695382 | 0.75 | MBOAT4 (0.35) | MAPK1HPGDKDRKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994139-B2 | Antiviral therapeutic agents | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| EP-1948664-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | MAPK1 2200/4885HPGD 2870/4885KDR 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.